Skip to main content
Profile picture for N. Lawrence Edwards, MD, MACP, MACR

N. Lawrence Edwards, MD, MACP, MACR

Dr. N. Lawrence Edwards is Professor of Medicine, Division of Rheumatology and Clinical Immunology, as well as Program Director and Vice Chairman of the Department of Medicine at the University of Florida in Gainesville. Dr. Edwards obtained his undergraduate training at the University of Notre Dame and his medical degree from the University of Miami School of Medicine. He completed his training in Rheumatology at the Rackham Arthritis Research Center and the Clinical Research Center, University of Michigan in Ann Arbor where he remained on the faculty as Director of Education and Training in the Division of Rheumatology. In 1983 he moved to the University of Florida where he is the former Chief of the Division of Rheumatology and Clinical Immunology and former Rheumatology Program Director for 15 years. For the past 22 years he has been Vice Chairman of the Department of Medicine and Program Director of the Medicine Residency Training Program at the University of Florida. Up on retirement in 2025, Dr Edwards retained Emeritus Professor status at the University of Florida

Dr. Edwards is an active member of many professional organizations including the American College of Rheumatology, American College of Physicians, and the Association of Program Directors in Internal Medicine. He is on the Executive Board of the Florida Chapter of ACP, the Co-chair of the Gout Interest Group for OMERACT since 2005 and the Chairman and CEO of the Gout and Uric Acid Education Society – a non-profit, patient education organization – for the past 20 years. He has authored 200 scientific articles, book chapters and reviews on the topics of hyperuricemia, gout, and purine metabolism. He is a Master of both the ACP and the ACR.

Articles By N. Lawrence Edwards, MD, MACP, MACR

Myth vs reality

Persistence of education and monitoring is crucial to optimal gout management

It is important that the misconceptions and myths held by the patient are discussed and dispelled and, most importantly, establish a clear understanding of “the plan” and the reason for initiating urate-lowering therapy (ULT).

Read Article
Gout pills injection

Problems with treatment adherence in the management of gout

Compared to common medical conditions such as hypertension, type 2 diabetes, hyperlipidemia or osteoporosis, where the reported drug adherence rates are between 50% to 70%, the drug adherence for gout is 37%.

Read Article
×